Chromosomal Microarray (CMA) Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510241036

Publication Date:

October 14, 2024

Pages:

112

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

Chromosomal Microarray (CMA) Testing is a genetic diagnostic technique that uses microarray technology to analyze an individual's DNA for chromosomal abnormalities, structural variations, and genetic disorders.
The global market for Chromosomal Microarray (CMA) Testing was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The advancement of genetic testing technologies drives the adoption of CMA testing. Healthcare providers, especially in prenatal and pediatric fields, rely on CMA to identify genetic causes of developmental and intellectual disabilities.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chromosomal Microarray (CMA) Testing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Chromosomal Microarray (CMA) Testing by region & country, by Type, and by Application.
The Chromosomal Microarray (CMA) Testing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chromosomal Microarray (CMA) Testing.
Market Segmentation
By Company
Baylor Genetics
MedGenome Labs
Centogene
GeneDx
Quest Diagnostics
LabCorp
Lineagen
Invitae
Illumina Inc.
CD Genomics
Thermo Fisher
Agilent
Segment by Type:
Single Nucleotide Polymorphism (SNP)
Comparative Genomic Hybridization (CGH)
Segment by Application
Medical
Laboratory
Clinical
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chromosomal Microarray (CMA) Testing manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Chromosomal Microarray (CMA) Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Chromosomal Microarray (CMA) Testing in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Chromosomal Microarray (CMA) Testing Product Introduction
1.2 Global Chromosomal Microarray (CMA) Testing Market Size Forecast
1.3 Chromosomal Microarray (CMA) Testing Market Trends & Drivers
1.3.1 Chromosomal Microarray (CMA) Testing Industry Trends
1.3.2 Chromosomal Microarray (CMA) Testing Market Drivers & Opportunity
1.3.3 Chromosomal Microarray (CMA) Testing Market Challenges
1.3.4 Chromosomal Microarray (CMA) Testing Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Chromosomal Microarray (CMA) Testing Players Revenue Ranking (2023)
2.2 Global Chromosomal Microarray (CMA) Testing Revenue by Company (2019-2024)
2.3 Key Companies Chromosomal Microarray (CMA) Testing Manufacturing Base Distribution and Headquarters
2.4 Key Companies Chromosomal Microarray (CMA) Testing Product Offered
2.5 Key Companies Time to Begin Mass Production of Chromosomal Microarray (CMA) Testing
2.6 Chromosomal Microarray (CMA) Testing Market Competitive Analysis
2.6.1 Chromosomal Microarray (CMA) Testing Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Chromosomal Microarray (CMA) Testing Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chromosomal Microarray (CMA) Testing as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Single Nucleotide Polymorphism (SNP)
3.1.2 Comparative Genomic Hybridization (CGH)
3.2 Global Chromosomal Microarray (CMA) Testing Sales Value by Type
3.2.1 Global Chromosomal Microarray (CMA) Testing Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Chromosomal Microarray (CMA) Testing Sales Value, by Type (2019-2030)
3.2.3 Global Chromosomal Microarray (CMA) Testing Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Medical
4.1.2 Laboratory
4.1.3 Clinical
4.1.4 Others
4.2 Global Chromosomal Microarray (CMA) Testing Sales Value by Application
4.2.1 Global Chromosomal Microarray (CMA) Testing Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Chromosomal Microarray (CMA) Testing Sales Value, by Application (2019-2030)
4.2.3 Global Chromosomal Microarray (CMA) Testing Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Chromosomal Microarray (CMA) Testing Sales Value by Region
5.1.1 Global Chromosomal Microarray (CMA) Testing Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Chromosomal Microarray (CMA) Testing Sales Value by Region (2019-2024)
5.1.3 Global Chromosomal Microarray (CMA) Testing Sales Value by Region (2025-2030)
5.1.4 Global Chromosomal Microarray (CMA) Testing Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
5.2.2 North America Chromosomal Microarray (CMA) Testing Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
5.3.2 Europe Chromosomal Microarray (CMA) Testing Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
5.4.2 Asia Pacific Chromosomal Microarray (CMA) Testing Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
5.5.2 South America Chromosomal Microarray (CMA) Testing Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
5.6.2 Middle East & Africa Chromosomal Microarray (CMA) Testing Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Chromosomal Microarray (CMA) Testing Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Chromosomal Microarray (CMA) Testing Sales Value
6.3 United States
6.3.1 United States Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
6.3.2 United States Chromosomal Microarray (CMA) Testing Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Chromosomal Microarray (CMA) Testing Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
6.4.2 Europe Chromosomal Microarray (CMA) Testing Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Chromosomal Microarray (CMA) Testing Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
6.5.2 China Chromosomal Microarray (CMA) Testing Sales Value by Type (%), 2023 VS 2030
6.5.3 China Chromosomal Microarray (CMA) Testing Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
6.6.2 Japan Chromosomal Microarray (CMA) Testing Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Chromosomal Microarray (CMA) Testing Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
6.7.2 South Korea Chromosomal Microarray (CMA) Testing Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Chromosomal Microarray (CMA) Testing Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
6.8.2 Southeast Asia Chromosomal Microarray (CMA) Testing Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Chromosomal Microarray (CMA) Testing Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Chromosomal Microarray (CMA) Testing Sales Value, 2019-2030
6.9.2 India Chromosomal Microarray (CMA) Testing Sales Value by Type (%), 2023 VS 2030
6.9.3 India Chromosomal Microarray (CMA) Testing Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Baylor Genetics
7.1.1 Baylor Genetics Profile
7.1.2 Baylor Genetics Main Business
7.1.3 Baylor Genetics Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.1.4 Baylor Genetics Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.1.5 Baylor Genetics Recent Developments
7.2 MedGenome Labs
7.2.1 MedGenome Labs Profile
7.2.2 MedGenome Labs Main Business
7.2.3 MedGenome Labs Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.2.4 MedGenome Labs Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.2.5 MedGenome Labs Recent Developments
7.3 Centogene
7.3.1 Centogene Profile
7.3.2 Centogene Main Business
7.3.3 Centogene Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.3.4 Centogene Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.3.5 GeneDx Recent Developments
7.4 GeneDx
7.4.1 GeneDx Profile
7.4.2 GeneDx Main Business
7.4.3 GeneDx Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.4.4 GeneDx Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.4.5 GeneDx Recent Developments
7.5 Quest Diagnostics
7.5.1 Quest Diagnostics Profile
7.5.2 Quest Diagnostics Main Business
7.5.3 Quest Diagnostics Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.5.4 Quest Diagnostics Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.5.5 Quest Diagnostics Recent Developments
7.6 LabCorp
7.6.1 LabCorp Profile
7.6.2 LabCorp Main Business
7.6.3 LabCorp Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.6.4 LabCorp Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.6.5 LabCorp Recent Developments
7.7 Lineagen
7.7.1 Lineagen Profile
7.7.2 Lineagen Main Business
7.7.3 Lineagen Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.7.4 Lineagen Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.7.5 Lineagen Recent Developments
7.8 Invitae
7.8.1 Invitae Profile
7.8.2 Invitae Main Business
7.8.3 Invitae Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.8.4 Invitae Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.8.5 Invitae Recent Developments
7.9 Illumina Inc.
7.9.1 Illumina Inc. Profile
7.9.2 Illumina Inc. Main Business
7.9.3 Illumina Inc. Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.9.4 Illumina Inc. Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.9.5 Illumina Inc. Recent Developments
7.10 CD Genomics
7.10.1 CD Genomics Profile
7.10.2 CD Genomics Main Business
7.10.3 CD Genomics Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.10.4 CD Genomics Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.10.5 CD Genomics Recent Developments
7.11 Thermo Fisher
7.11.1 Thermo Fisher Profile
7.11.2 Thermo Fisher Main Business
7.11.3 Thermo Fisher Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.11.4 Thermo Fisher Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.11.5 Thermo Fisher Recent Developments
7.12 Agilent
7.12.1 Agilent Profile
7.12.2 Agilent Main Business
7.12.3 Agilent Chromosomal Microarray (CMA) Testing Products, Services and Solutions
7.12.4 Agilent Chromosomal Microarray (CMA) Testing Revenue (US$ Million) & (2019-2024)
7.12.5 Agilent Recent Developments
8 Industry Chain Analysis
8.1 Chromosomal Microarray (CMA) Testing Industrial Chain
8.2 Chromosomal Microarray (CMA) Testing Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Chromosomal Microarray (CMA) Testing Sales Model
8.5.2 Sales Channel
8.5.3 Chromosomal Microarray (CMA) Testing Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Baylor Genetics
MedGenome Labs
Centogene
GeneDx
Quest Diagnostics
LabCorp
Lineagen
Invitae
Illumina Inc.
CD Genomics
Thermo Fisher
Agilent

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂